Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 13/20 | 0.52 |
| ▸ | CA1 | P00915 | 12/20 | 0.50 |
| ▸ | CA2 | P00918 | 12/20 | 0.50 |
| ▸ | CA12 | O43570 | 6/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.48 |
| ▸ | HTR3A | P46098 | 2/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17522976 | 0.93 | CA9 (0.49) | CA9CA1CA2CA12ADORA3 | |
| SCHEMBL18163373 | 0.82 | CA9 (0.68) | CA9CA1CA2CA12HTR3A | |
| SCHEMBL18517643 | 0.81 | CA9 (0.70) | CA9CA1CA2CA12CA14 | |
| SCHEMBL20401651 | 0.76 | USP2 (0.59) | CA9CA1CA2CA12ADORA3 | |
| SCHEMBL21151146 | 0.76 | CA9 (0.73) | CA9CA1CA2CA12HTR3A | |
| SCHEMBL21728989 | 0.76 | CA9 (0.73) | CA9CA1CA2CA12HTR3A | |
| SCHEMBL17522977 | 0.75 | CA9 (0.64) | CA9CA1CA2CA12CA14 | |
| SCHEMBL10035691 | 0.75 | CA9 (0.65) | CA9CA1CA2CA12HTR3A | |
| SCHEMBL17522975 | 0.74 | CA9 (0.73) | CA9CA1CA2CA12CA14 | |
| SCHEMBL13915130 | 0.74 | CA9 (0.73) | CA9CA1CA2CA12ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046584-A1 | COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS FOR PLAQUE SOFTENING | ALUMEND, LLC (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046584-A1 | COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS FOR PLAQUE SOFTENING | ALUMEND, LLC (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046584-A1 | COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS FOR PLAQUE SOFTENING | APOB, PLG, LIPG | CA9 781/4885CA1 502/4885CA2 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.